In the face of this evidence, USIC argued that "a doctor's opinion that there is a high probability of
relapse is not objective or even reliable evidence of a current disability." But the court felt that USIC was just reiterating the same argument: that no risk of
relapse could qualify for LTD benefits under its policy, when in fact no such exclusion existed.
Over that time, those receiving ACTH had fewer
relapses, or 0.08 cumulative
relapses per patient compared to 0.8
relapses per patient for those receiving methylprednisolone.
Part 1 was completed when a patient presented with a new MS
relapse to evaluate the patient's
relapse symptoms and how the symptoms affect activities of daily living (ADL) and overall function, as well as the patient's response to past treatments for previous
relapses, as a means of guiding treatment selection (the choice of
relapse treatment was entirely at the discretion of the treating clinician and did not affect patient eligibility).
The most important model that has been used for assessing the
relapse process is Marlatt's cognitive-behavior model (Cummings, Gordon, & Marlatt, 1980; Marlatt & Gordon, 1985), which has been updated since its original publication (Marlatt, 1996; Marlatt & Donovan, 2005; Witkiewitz & Marlatt, 2004).
The data were obtained from the medical histories of patients and the following characteristics were analyzed: sex, age at the time of diagnosis, germinal center B-cell (GCB)/non-GCB subtype [14], initial treatment, time of disease
relapse (early
relapse [less than or equal to] 12 months from the end of the first-line treatment, late
relapse > 12 months from the end of the first line of treatment).
The researchers found that compared with children, AYA experienced an increased risk of on-therapy
relapse (hazard ratio, 10.5).
In differential diagnosis of exudative detachment there are uveal fusion syndrome, choroidopathy, Harada syndrome, choroid detachment, choroidal neovascularisation, and severe intraocular hypotonic but with consideration of patients age and primary illness it was thought with orbital
relapse. In ALL patients who were in remission period, 25 isolated case series were reported.
These children were randomly assigned to receive fluticasone propionate or vehicle twice weekly on consecutive days for 16 weeks; treatment was stopped then or at
relapse.
Some say
relapse is part of the recovery process, but it does not have to be.
The following variables were considered as potential risk factors/predictors of frequent
relapses based on previous studies: age at onset, sex, inadequate steroid therapy (less than 8 weeks) at onset, time of first
relapse (time from the start of initial treatment to first
relapse), and concurrent infections during
relapses.
Immunophenotypic features were compatible with AML clone found at diagnosis and first
relapse, although CD56 was dim positive.